other

Updated:

Sirnaomics

Sirnaomics, a biopharmaceutical company based in Gaithersburg, United States, was founded in 2007. It develops therapeutics for critical human diseases using...

Sirnaomics

Sirnaomics, a biopharmaceutical company based in Gaithersburg, United States, was founded in 2007. It develops therapeutics for critical human diseases using RNA interference technology. The company has secured $278.967 million in total funding.

General information

Firm type

other

Year founded

2007

Location

Region

North America

Country

United States

City

Gaithersburg

Corporate office

Gaithersburg, MD, United States

Additional offices

Las Vegas, NV, United States · Shenzhen, China

Sector focus

Biotech & PharmaceuticalsRNA Therapeutics

Frequently asked questions

What investment stages does Sirnaomics typically target?

Sirnaomics allocates capital to internal R&D and clinical trials for its own pipeline, rather than making external investments. Its stage coverage spans preclinical through Phase IIb clinical trials, as seen with programs like STP705 and STP122G (per the firm).

Which sectors does Sirnaomics explicitly avoid?

The firm focuses exclusively on RNA therapeutics for cancers, fibrosis, antivirals, cardiometabolic diseases, and medical aesthetics. It has no disclosed exposure to traditional asset classes like real estate, private equity, or hedge funds.

How does Sirnaomics source proprietary deal flow?

Sirnaomics does not source external deal flow; its pipeline is built internally using its two proprietary delivery platforms, PNP and GalNAc (per the firm).

Does Sirnaomics participate in fund commitments or only direct deals?

Sirnaomics does not commit to external funds; its capital is deployed directly into its own R&D and clinical development programs.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Gaithersburg other profiles